Lupagen

Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C&GT production and delivery platform. Lupagen’s systems are deployed using standard apheresis-based platform customized for a diverse range of gene therapies that require targeted genetic or cellular modification of selective populations of a patient’s circulating peripheral blood mononuclear cells.

网站

https://www.lupagen.com

Lupagen的外部链接

所属行业

生物技术

规模

2-10 人

总部

Dallas，Texas

类型

私人持股

创立

2017

领域

Biotechnology、Cell therapy、Gene therapy、Immunotherapy、Oncology、Rare Disease和Autoimmune